Document is current
Any future updates will be listed below
-
Authors
Hamada, Riku
Kaku, Yoshitsugu
Inaba, Aya
Kaito, Hiroshi
Kimata, Takahisa
Kondo, Shuji
Sako, Mayumi
Sato, Mai
Sugimoto, Keisuke
Tanaka, Seiji
Nagaoka, Yoshinobu
Nozu, Kandai
Hashimoto, Junya
Miura, Kenichiro
Yamamoto, Masaki
Kawai, Fujimi
Maruyama, Shoichi
Ishikura, Kenji
- License Information
-
More Information
Article History
Accepted: 27 January 2025
First Online: 10 March 2025
Declarations
:
: All members engaged in the guideline development submitted Conflicts of Interest declaration forms, which are retained by the Japanese Society for Pediatric Nephrology. Honoraria: Shoichi Maruyama (Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd.), Grants received: Shoichi Maruyama (Bristol-Myers Squibb Company), Kenji Ishikura (Asahi Kasei Pharma Corporation, Novartis Pharma K.K.), Scholarship endowment: Shoichi Maruyama (Astellas Pharma Inc., Alexion Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Company Limited., Torii Pharmaceutical Co., Ltd., Pfizer Japan Inc., MOCHIDA PHARMACEUTICAL CO., LTD., Asahi Kasei Pharma Corporation, Chugai Pharmaceutical Co., Ltd., TEIJIN PHARMA LIMITED., Merck Sharp & Dohme LLC., Mitsubishi Tanabe Pharma Corporation., Baxter.). The other authors have declared that no conflict of interest exists.
